In Brief: FDA Warning Letters; Premium Private Label Supplements Grow; Reckitt Invests In R&D Facility
This article was originally published in The Tan Sheet
Executive Summary
Inflammation drug claims draw warning; warning lists improper sexual health claims; mole removal claims inappropriate for OTCs; salmonella-tainted carob powder recalls spread; premium supplements added to grow private label sales; and Reckitt builds consumer health R&D center.